Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 9829

Next Previous
Drug Profile

AZD 9829

Alternative Names: AZD-9829

Latest Information Update: 04 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 30 Sep 2025 Discontinued - Phase-I/II for Haematological malignancies (Second-line therapy or greater) in United Kingdom, Taiwan, Spain, Japan, Italy, Germany, China, Australia, South Korea, USA (IV) due to efficacy, before September 2025 (AstraZeneca pipeline, December 2025)
  • 13 Jun 2024 Pharmacodynamics data from a preclinical studies in Haematological malignancies presented at the 29th Congress of the European Haematology Association, 2024 (EHA-2024)
  • 31 Jan 2024 Phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater) in South Korea (IV) (NCT06179511)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top